These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 33198671)

  • 21. Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer.
    Wirth LJ; Brose MS; Sherman EJ; Licitra L; Schlumberger M; Sherman SI; Bible KC; Robinson B; Rodien P; Godbert Y; De La Fouchardiere C; Newbold K; Nutting C; Misir S; Xie R; Almonte A; Ye W; Cabanillas ME
    J Clin Oncol; 2021 Jul; 39(21):2359-2366. PubMed ID: 33961488
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT.
    Okusaka T; Ikeda K; Kudo M; Finn R; Qin S; Han KH; Cheng AL; Piscaglia F; Kobayashi M; Sung M; Chen M; Wyrwicz L; Yoon JH; Ren Z; Mody K; Dutcus C; Tamai T; Ren M; Hayato S; Kumada H
    J Gastroenterol; 2021 Jun; 56(6):570-580. PubMed ID: 33948712
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma.
    Hutson TE; Michaelson MD; Kuzel TM; Agarwal N; Molina AM; Hsieh JJ; Vaishampayan UN; Xie R; Bapat U; Ye W; Jain RK; Fishman MN
    Eur Urol; 2021 Aug; 80(2):162-170. PubMed ID: 33867192
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of Age on the Efficacy and Safety of Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer in the Phase III SELECT Trial.
    Brose MS; Worden FP; Newbold KL; Guo M; Hurria A
    J Clin Oncol; 2017 Aug; 35(23):2692-2699. PubMed ID: 28613956
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A single-arm, multicenter, open-label phase 2 trial of surufatinib in patients with unresectable or metastatic biliary tract cancer.
    Xu J; Bai Y; Sun H; Bai C; Jia R; Li Y; Zhang W; Liu L; Huang C; Guan M; Zhou J; Su W
    Cancer; 2021 Nov; 127(21):3975-3984. PubMed ID: 34355801
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A prospective multicenter phase II study of FOLFIRINOX as a first-line treatment for patients with advanced and recurrent biliary tract cancer.
    Takahara N; Nakai Y; Isayama H; Sasaki T; Morine Y; Watanabe K; Ueno M; Ioka T; Kanai M; Kondo S; Okano N; Koike K
    Invest New Drugs; 2023 Feb; 41(1):76-85. PubMed ID: 36459291
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Extended Real-World Observation of Patients Treated with Sorafenib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Impact of Lenvatinib Salvage Treatment: A Korean Multicenter Study.
    Oh HS; Shin DY; Kim M; Park SY; Kim TH; Kim BH; Kim EY; Kim WB; Chung JH; Shong YK; Lim DJ; Kim WG
    Thyroid; 2019 Dec; 29(12):1804-1810. PubMed ID: 31592739
    [No Abstract]   [Full Text] [Related]  

  • 28. Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study.
    Buzzoni R; Pusceddu S; Bajetta E; De Braud F; Platania M; Iannacone C; Cantore M; Mambrini A; Bertolini A; Alabiso O; Ciarlo A; Turco C; Mazzaferro V
    Ann Oncol; 2014 Aug; 25(8):1597-603. PubMed ID: 24827133
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of FOLFIRINOX as salvage treatment in advanced biliary tract cancer: an open-label, single arm, phase 2 trial.
    Belkouz A; de Vos-Geelen J; Mathôt RAA; Eskens FALM; van Gulik TM; van Oijen MGH; Punt CJA; Wilmink JW; Klümpen HJ
    Br J Cancer; 2020 Mar; 122(5):634-639. PubMed ID: 31919404
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lenvatinib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Candidate Biomarkers Associated with Survival: A Multicenter Study in Korea.
    Song E; Kim M; Kim EY; Kim BH; Shin DY; Kang HC; Ahn BC; Kim WB; Shong YK; Jeon MJ; Lim DJ
    Thyroid; 2020 May; 30(5):732-738. PubMed ID: 31910091
    [No Abstract]   [Full Text] [Related]  

  • 31. Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial.
    Zhang W; Tong S; Hu B; Wan T; Tang H; Zhao F; Jiao T; Li J; Zhang Z; Cai J; Ye H; Wang Z; Chen S; Wang Y; Li X; Wang F; Cao J; Tian L; Zhao X; Chen M; Wang H; Cai S; Hu M; Bai Y; Lu S
    J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37730273
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme.
    Moehler M; Maderer A; Schimanski C; Kanzler S; Denzer U; Kolligs FT; Ebert MP; Distelrath A; Geissler M; Trojan J; Schütz M; Berie L; Sauvigny C; Lammert F; Lohse A; Dollinger MM; Lindig U; Duerr EM; Lubomierski N; Zimmermann S; Wachtlin D; Kaiser AK; Schadmand-Fischer S; Galle PR; Woerns M;
    Eur J Cancer; 2014 Dec; 50(18):3125-35. PubMed ID: 25446376
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes.
    Haddad RI; Schlumberger M; Wirth LJ; Sherman EJ; Shah MH; Robinson B; Dutcus CE; Teng A; Gianoukakis AG; Sherman SI
    Endocrine; 2017 Apr; 56(1):121-128. PubMed ID: 28155175
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lenvatinib combined with PD-1 inhibitor plus Gemox chemotherapy versus plus HAIC for advanced biliary tract cancer.
    Zhang T; Zhu C; Zhang N; Zhang L; Wang S; Xun Z; Xu Y; Yang X; Lu X; Zhao H
    Int Immunopharmacol; 2024 Mar; 129():111642. PubMed ID: 38325044
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FDA Approval Summary: Lenvatinib for Progressive, Radio-iodine-Refractory Differentiated Thyroid Cancer.
    Nair A; Lemery SJ; Yang J; Marathe A; Zhao L; Zhao H; Jiang X; He K; Ladouceur G; Mitra AK; Zhou L; Fox E; Aungst S; Helms W; Keegan P; Pazdur R
    Clin Cancer Res; 2015 Dec; 21(23):5205-8. PubMed ID: 26324740
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.
    Lee CH; Shah AY; Rasco D; Rao A; Taylor MH; Di Simone C; Hsieh JJ; Pinto A; Shaffer DR; Girones Sarrio R; Cohn AL; Vogelzang NJ; Bilen MA; Gunnestad Ribe S; Goksel M; Tennøe ØK; Richards D; Sweis RF; Courtright J; Heinrich D; Jain S; Wu J; Schmidt EV; Perini RF; Kubiak P; Okpara CE; Smith AD; Motzer RJ
    Lancet Oncol; 2021 Jul; 22(7):946-958. PubMed ID: 34143969
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FDA Supplemental Approval Summary: Lenvatinib for the Treatment of Unresectable Hepatocellular Carcinoma.
    Nair A; Reece K; Donoghue MB; Yuan WV; Rodriguez L; Keegan P; Pazdur R
    Oncologist; 2021 Mar; 26(3):e484-e491. PubMed ID: 33044793
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lenvatinib: Role in thyroid cancer and other solid tumors.
    Cabanillas ME; Habra MA
    Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term follow-up and exploratory analysis of lenvatinib in patients with metastatic or recurrent thymic carcinoma: Results from the multicenter, phase 2 REMORA trial.
    Niho S; Sato J; Satouchi M; Itoh S; Okuma Y; Mizugaki H; Murakami H; Fujisaka Y; Kozuki T; Nakamura K; Machida R; Ohe Y; Tamai T; Ikezawa H; Yamamoto N
    Lung Cancer; 2024 May; 191():107557. PubMed ID: 38626709
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial.
    Motzer RJ; Hutson TE; Glen H; Michaelson MD; Molina A; Eisen T; Jassem J; Zolnierek J; Maroto JP; Mellado B; Melichar B; Tomasek J; Kremer A; Kim HJ; Wood K; Dutcus C; Larkin J
    Lancet Oncol; 2015 Nov; 16(15):1473-1482. PubMed ID: 26482279
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.